Sitemap
- Home
- About Us
- Your Health
- Science & Innovation
- Our responsibility
- Careers
- Investors
-
Media
-
Press releases
-
2022
- Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old
- Media Update: New two-year efficacy and safety data for tolebrutinib, Sanofi’s investigational, brain-penetrant and bioactive BTK inhibitor, to be presented at ECTRIMS 2022
- Press Release: Continued strong growth in Q3 with key regulatory milestones achieved
- Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
- Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
- Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
- Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
-
2021
-
2020
-
2019
-
2018
-
2022
- Articles
- Contacts
- Media Alert
-
Press releases